The Asan Foundation

Daewoong Pharmaceutical Co., Ltd.

Jung-Min Koh

Seung Hun Lee

Beom-jun Kim

Young-Sun Lee

Ghi Su Kim

A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.

Growing community of inventors

Seoul, South Korea

Jung-Min Koh